Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 11/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quazinone SCHEMBL2463520 | 1.00 | PDE3B (1.00) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| Quazinone SCHEMBL11279841 | 0.99 | PDE3B (0.97) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| SCHEMBL11158019 | 0.85 | PDE3B (0.74) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| Hydrochloric Acid SCHEMBL11280120 | 0.84 | PDE3B (0.73) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| SCHEMBL11400630 | 0.84 | PDE3B (0.73) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| SCHEMBL11398470 | 0.84 | PDE3B (0.73) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| Hydrochloric Acid SCHEMBL11278036 | 0.83 | PDE3B (0.71) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| SCHEMBL11278398 | 0.82 | PDE3B (0.70) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| SCHEMBL11279375 | 0.82 | PDE3B (0.69) | PDE3BPDE3ACYP1A2TSHRLMNA | |
| Hydrochloric Acid SCHEMBL11388525 | 0.81 | PDE3B (0.68) | PDE3BPDE3ACYP1A2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2023118113-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-06-29 | — | — | WO | claimed |
| EP-4201403-A1 | COMPOUNDS TIRAPAZAMINE AND QUAZINONE FOR USE IN THE TREATMENT OF GM2 GANGLIOSIDOSES | Som Innovation Biotech, S.L. (ES) | 2023-06-28 | — | — | EP | claimed |
| CN-217740556-U | Four-in-one packaging support, LED lamp bead and full-color display screen | 厦门市信达光电科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115207185-A | Four-in-one packaging support, LED lamp bead and full-color display screen | 厦门市信达光电科技有限公司 | 2022-10-18 | — | — | CN | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| US-6337325-B1 | IMMUNOSUPRESSANTS, AUTOIMMUNE DISEASES, DERMATITIS, RHINITIS, UVEITIS, ANTIDIABETIC AGENTS, CYSTIC FIBROSIS OR LIVER FIBROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-08 | — | — | US | claimed |
| EP-0777482-B1 | COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES | HOECHST AG (DE) | 2001-11-14 | — | — | EP | claimed |
| US-6297243-B1 | TREATING OSTEOPENIA THAT ACCOMPANIES THE MENOPAUSE | NOVO NORDISK A/S (DK) | 2001-10-02 | — | — | US | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885CYP1A2 3874/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885CYP1A2 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.